{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-033614","form_type":"8-K","ticker":"CTNM","cik":"0001855175","company_name":"Contineum Therapeutics, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.084667+00:00","generated_at":"2026-05-30T04:49:29.427710+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Contineum reports Q3 2024 cash $213.9M, VISTA trial enrollment on track","bullets":["Cash, equivalents and marketable securities $213.9M as of Sept 30, 2024 (vs $125.2M at end of 2023).","R&D expense $9.7M (+$3.2M YoY) driven by VISTA Phase 2 trial and PIPE-791 toxicology studies.","VISTA trial for PIPE-307 in RRMS two-thirds enrolled; full enrollment expected first half 2025.","Pending MHRA authorization, Phase 1b PET trial for PIPE-791 to start Dec 2024 with data in H1 2025.","Janssen confirms on track to initiate Phase 2 trial of PIPE-307 in depression."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-033614","json":"https://secwatch.observer/filing/0001437749-24-033614.json","markdown":"https://secwatch.observer/filing/0001437749-24-033614.md","text":"https://secwatch.observer/filing/0001437749-24-033614.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855175/000143774924033614/0001437749-24-033614-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855175/000143774924033614/cont20241029_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:49:29.427710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}